Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, MeMed Expand Distribution Partnership

NEW YORK – Danaher subsidiary Beckman Coulter Diagnostics announced Tuesday that it has expanded a previous partnership with Israeli firm MeMed to distribute the MeMed BV assay and MeMed Key analyzer. 

The new distribution agreement builds on a previous partnership between the two companies to develop a MeMed BV-based assay for Beckman Coulter's portfolio of Access immunoassay analyzers, the firms said in a statement. 

MeMed's BV immunoassay distinguishes between bacterial and viral infections and runs on the MeMed Key immunoassay analyzer. It uses a machine learning-based algorithm to combine measurements of three host-immune proteins, TRAIL, IP-10, and C-reactive protein, in a score that indicates the likelihood of a bacterial or viral infection. 

The expanded agreement "focuses on two main objectives: first, to educate and prime the market to accelerate the adoption of MeMed BV once it's cleared for use on Beckman Coulter's core-lab immunoassay analyzers; second, to broaden patient access to MeMed BV through a strategic hub-and-spoke model," MeMed CEO and Cofounder Eran Eden said in a statement. 

"By combining the capabilities of Beckman Coulter's analyzers with the MeMed Key's ability to deliver results directly from whole blood within minutes, we're creating a synergistic ecosystem that aids clinicians in distinguishing between bacterial and viral infections with unprecedented ease and precision," Eden added.